These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 7835380)
1. The clinical profile of sumatriptan: efficacy in migraine. Pilgrim AJ Eur Neurol; 1994; 34 Suppl 2():26-34. PubMed ID: 7835380 [TBL] [Abstract][Full Text] [Related]
2. Sumatriptan. An updated review of its use in migraine. Perry CM; Markham A Drugs; 1998 Jun; 55(6):889-922. PubMed ID: 9617601 [TBL] [Abstract][Full Text] [Related]
3. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Plosker GL; McTavish D Drugs; 1994 Apr; 47(4):622-51. PubMed ID: 7516861 [TBL] [Abstract][Full Text] [Related]
4. Sumatriptan (subcutaneous route of administration) for acute migraine attacks in adults. Derry CJ; Derry S; Moore RA Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD009665. PubMed ID: 22336869 [TBL] [Abstract][Full Text] [Related]
5. Migraine and cluster headache--their management with sumatriptan: a critical review of the current clinical experience. Wilkinson M; Pfaffenrath V; Schoenen J; Diener HC; Steiner TJ Cephalalgia; 1995 Oct; 15(5):337-57. PubMed ID: 8536293 [TBL] [Abstract][Full Text] [Related]
6. Transdermal sumatriptan for acute treatment of migraineurs with baseline nausea. Schulman EA Headache; 2012 Feb; 52(2):204-12. PubMed ID: 22229837 [TBL] [Abstract][Full Text] [Related]
7. AVP-825 breath-powered intranasal delivery system containing 22 mg sumatriptan powder vs 100 mg oral sumatriptan in the acute treatment of migraines (The COMPASS study): a comparative randomized clinical trial across multiple attacks. Tepper SJ; Cady RK; Silberstein S; Messina J; Mahmoud RA; Djupesland PG; Shin P; Siffert J Headache; 2015 May; 55(5):621-35. PubMed ID: 25941016 [TBL] [Abstract][Full Text] [Related]
8. Early intervention in migraine with sumatriptan tablets 50 mg versus 100 mg: a pooled analysis of data from six clinical trials. Winner P; Landy S; Richardson M; Ames M Clin Ther; 2005 Nov; 27(11):1785-94. PubMed ID: 16368449 [TBL] [Abstract][Full Text] [Related]
9. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Sheftell FD; Dahlöf CG; Brandes JL; Agosti R; Jones MW; Barrett PS Clin Ther; 2005 Apr; 27(4):407-17. PubMed ID: 15922814 [TBL] [Abstract][Full Text] [Related]
10. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group. Cephalalgia; 1999 May; 19(4):232-40. PubMed ID: 10376168 [TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine. Cady RK; Munjal S; Cady RJ; Manley HR; Brand-Schieber E J Headache Pain; 2017 Dec; 18(1):17. PubMed ID: 28176235 [TBL] [Abstract][Full Text] [Related]
12. Sumatriptan: pharmacological basis and clinical results. Dahlöf CG Curr Med Res Opin; 2001; 17 Suppl 1():s35-45. PubMed ID: 12463276 [TBL] [Abstract][Full Text] [Related]
13. Pharmacological synergy: the next frontier on therapeutic advancement for migraine. Blumenfeld A; Gennings C; Cady R Headache; 2012 Apr; 52(4):636-47. PubMed ID: 22221151 [TBL] [Abstract][Full Text] [Related]
14. Twelve-month tolerability and efficacy study of NP101, the sumatriptan iontophoretic transdermal system. Smith TR; Goldstein J; Singer R; Pugach N; Silberstein S; Pierce MW Headache; 2012 Apr; 52(4):612-24. PubMed ID: 22352764 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. Lampl C; Voelker M; Diener HC J Neurol; 2007 Jun; 254(6):705-12. PubMed ID: 17406776 [TBL] [Abstract][Full Text] [Related]
16. An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with subcutaneous sumatriptan. Landy SH; Tepper SJ; Wein T; Schweizer E; Ramos E Headache; 2013 Jan; 53(1):118-125. PubMed ID: 23148799 [TBL] [Abstract][Full Text] [Related]
17. Innovative delivery systems for migraine: the clinical utility of a transdermal patch for the acute treatment of migraine. Rapoport AM; Freitag F; Pearlman SH CNS Drugs; 2010 Nov; 24(11):929-40. PubMed ID: 20932065 [TBL] [Abstract][Full Text] [Related]
18. Subcutaneous sumatriptan in the acute treatment of migraine in patients using dihydroergotamine as prophylaxis. French Migraine Network Bordeaux-Lyon-Grenoble. Henry P; d'Allens H Headache; 1993 Sep; 33(8):432-5. PubMed ID: 8262783 [TBL] [Abstract][Full Text] [Related]
19. Oral sumatriptan for migraine in children and adolescents: a randomized, multicenter, placebo-controlled, parallel group study. Fujita M; Sato K; Nishioka H; Sakai F Cephalalgia; 2014 Apr; 34(5):365-75. PubMed ID: 24163282 [TBL] [Abstract][Full Text] [Related]
20. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Wendt J; Cady R; Singer R; Peters K; Webster C; Kori S; Byrd S Clin Ther; 2006 Apr; 28(4):517-26. PubMed ID: 16750463 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]